Atlas Trials

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Clinical trial NCT02431559 · COMPLETED

Trial details

NCT number
NCT02431559
Sponsor
Ludwig Institute for Cancer Research
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2015-12-02
Primary completion
2018-12-11
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.